Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year

Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year
Champions Oncology (NASDAQ:CSBR) shares fell 23% in a month, yet surged 47% in a year. The company transitioned from loss to profit, showing growth potential. Revenue growth of 19% and modest CEO pay suggest a positive outlook.